

It is indeed a great pleasure and honor for me to introduce this book entitled *Key Leaders' Opinion on Novel Progress in Treatment of Kidney Cancer*, published by AME publishing company.

The landscape of kidney cancer has dramatically changed over the last two decades. As we improved our understanding of the biology of the disease, more conservative approaches to its management have been implemented. New imaging modalities are being explored and biopsy techniques are being adopted by many with the aim of better define the disease and predict his behavior. Active surveillance and ablation have come to stage as reliable options in selected cases. The modern idea of “precision surgery” aims to combine the best oncological outcomes with maximal functional preservation. Nephron sparing surgery techniques have been refined and robotic surgery allowed to exponentially expand the role of minimally invasive partial nephrectomy. A revolution is undergoing in the field of systemic therapy for advanced kidney cancer as new drugs and combinations have shown their efficacy, and the concept of personalized therapy becomes more and more popular. Several areas of investigation, both at bench and bedside, remain both exciting and challenging. From the discovery of new diagnostic modalities and biomolecular markers to the definition of a better decision process in disease management or follow up schedule, from the investigation of neo-adjuvant and adjuvant therapies to the role of cytoreductive nephrectomy in advanced disease. More work needs to be done and we should stay tuned for future developments, of which we can catch an intriguing glimpse while reading this book.

In summary, this is a unique collection of articles on different topics related to kidney cancer, and opinion leaders from all over the world contributed to this comprehensive work. I would like to commend the AME publishing team for their terrific work in the editing process, and I am sure the readers will find this a stimulating and engaging reading!



**Riccardo Autorino, MD, PhD, FEBU**

Associate Professor of Surgery (Urology);

Director, Urologic Oncology, Division of Urology, VCU Health;

Associate Member, Developmental Therapeutics, VCU Massey Cancer Center,

Richmond, VA, USA